Abstract
We evaluated the reactogenicity and immunogenicity of an acellular pertussis vaccine in 24 subjects affected by Down's syndrome and in 10 normal infants. Neither general nor local adverse reactions were observed in either group of subjects. The new acellular vaccine administration elicited protective levels of antibodies in all the subjects with Down's syndrome, although the geometric mean titres of IgG antibodies againstBordetella pertussis in these subjects were significantly lower than in normal controls.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Booy R, Aitken SJM, Taylor S et al (1992) Immunogenicity of combined diphtheria-tetanus and pertussis vaccine given at 2, 3, and 4 months versus 3, 5 and 9 months of age. Lancet 339:507–510
Cherry JD, Brunell PA, Golden GS, Karzan DT (1988) Report of the task force on “pertussis and pertussis immunization 1988”. Pediatrics 81:933
Gordon MC, Sinha SK (1971) Antibody responses to influenza vaccine in patients with Down's syndrome. Am J Ment Defic 75:391–397
Hawkes RA, Boughton CR, Scroeter DR (1978) The antibody response of instituzionalized Down's syndrome patients to seven microbial antigens. Clin Exp Immunol 31:298–303
Hollinger Blaine F, Goyal RK, Hersch T, Powell HC, Schulman RJ, Melnick JL (1972) Immune response to hepatitis virus type B in Down's syndrome and other mentally retarded patients. Am J Epidemiol 95:356–362
Illingworth R (1981) Toxicity of pertussis vaccine. Br Med J 285:210–211
Menkes JH, Kinsbourne M (1990) Workshop on neurologic complications of pertussis and pertussis vaccinations. Neuropediatrics 21:171–175
Novo E, Garcia MI, Lavergne J (1993) Non specific immunity in Down syndrome: a study of chemotaxis, phagocytosis, oxidative metabolism, and cell surface marker expression of polymorphonuclear cells. Am J Med Genet 46:384–391
Nurmi T, Leinonen M, Haiva WM, Tilikainen A, Konvalainen K (1982) Antibody response to pneumococcal vaccine in patients with trisomy 21 (Down's syndrome). Clin Exp Immunol 48:485–490
Podda A, Nencioni L, Marsili, I, et al (1991) Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 9:741–745
Preston NW (1994) Pertussis vaccination: neither panic nor complacency. Lancet 2:491–492
Stewart GT (1979) Toxicity and pertussis vaccine: frequency and possibility of reactions. J Epidemiol Community Health 32:150
Thomson RG, Rowlins MD, James OFW, Tyrer SP, Codd A (1989) Prevalence of hepatitis B in mental handicap hospital. Lancet 1:44–45
Wahl M, Harmadssan S, Iwarsen S (1983) Immune responses to hepatitis B vaccine in the mentally retarded. J. Infect 7 [Suppl 1]:47
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li Volti, S., Mattina, T., Mauro, L. et al. Safety and effectiveness of an acellular pertussis vaccine in subjects with Down's syndrome. Child's Nerv Syst 12, 100–102 (1996). https://doi.org/10.1007/BF00819505
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00819505